Vaccinazione anti-HPV in Italia e in Europa: stato dell’arte e criticità

Translated title of the contribution: [Autom. eng. transl.] Anti-HPV vaccination in Italy and Europe: state of the art and critical issues

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

[Autom. eng. transl.] INTRODUCTION: Human Papilloma Virus (HPV) infection is extremely common in the population: it is estimated, in fact, that at least 75% of sexually active women become infected during their lives with an HPV virus of any type, and that beyond 50% with a high-risk cancer; among these, serotypes 16 and 18 are responsible for over 70% of cervical cancer cases, the second most common neoplasm in the European Union in women between 15 and 44 years. Every year in the world there are about 500,000 new cases of cervical cancer and 250,000 deaths and in Italy about 3500 new cases and 1000 deaths. The HPV vaccine, in association with screening, represents an important tool for the control of the pathology. Objectives of this work were: analyzing supply policies and vaccination coverage rates, comparing Italy with other European countries, as well as investigating the possible critical issues related to the spread of the vaccine. MATERIALS AND METHODS: A review of the scientific literature was conducted during the period July 2013 - May 2014, to evaluate the anti-HPV vaccine supply policies and coverage rates in European countries and Italian regions. The main electronic databases, institutional sites and gray literature available were consulted. In particular, for European data reference was made to the reports of the European Center for Disease Prevention and Control (ECDC) and for the Italian ones to the periodic reports prepared by the Epidemiology Department of Infectious Diseases of the National Center for Epidemiology Surveillance and Health Promotion (CNEPS) of the Istituto Superiore di Sanità (ISS). RESULTS: In the European Union (EU), according to data published by the ECDC in September 2012, 19 countries out of 29 have implemented routine HPV vaccination programs and 10 of these have also introduced catch-up programs to try to achieve the highest level of vaccination coverage. In the different European countries there is heterogeneity regarding vaccination implementation strategies, at the age of vaccination (from 9 to 18 years) and at the age of catch-up programs (12-40 years). The countries with the highest vaccination coverage rates are Portugal (84%), the United Kingdom (80%) and Denmark (79%), while the lowest coverage is found in Luxembourg (17%). In Italy, anti-HPV vaccination is offered free of charge and actively to twelve-year-olds in all Italian regions since the end of 2007. The right to free HPV vaccination is maintained over time in most regions. Furthermore, several Regions have extended the active and free offer of vaccination to other age groups in addition to the twelve and most have provided a facilitated payment for the age groups that are not the subject of an active call. The most recent data available, updated as of December 31, 2013, show a wide range of vaccination coverage among the Regions for all cohorts. The coverage rate for 3 vaccination doses for the 1997 cohort (before which the vaccine was offered) fluctuates between 26% of the Autonomous Province of Bolzano and 86.4% of Sardinia, with a national average of 69 , 5%. CONCLUSIONS: From the available data it is clear that, despite the efforts made by individual Member States, coverage rates are lower than expected in many EU countries. This is also true in Italy, where coverage levels for anti-HPV vaccination are still far from reaching a ≥ 95% quota that was set by the Agreement of 12/20/2007 as a target to be reached in 5 years . In light of the difficulty of achieving this goal, the 2012-2014 National Vaccine Prevention Plan has set new targets, establishing that the vaccination coverage for 3 HPV doses should and
Translated title of the contribution[Autom. eng. transl.] Anti-HPV vaccination in Italy and Europe: state of the art and critical issues
Original languageItalian
Title of host publicationAtti del 47° Congresso Nazionale della Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI)-Poster
Pages739-740
Number of pages2
Publication statusPublished - 2014
Event47° Congresso Nazionale della Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI) - Riccione
Duration: 1 Oct 20144 Oct 2014

Conference

Conference47° Congresso Nazionale della Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI)
CityRiccione
Period1/10/144/10/14

Keywords

  • Human Papilloma Virus
  • Vaccination

Fingerprint

Dive into the research topics of '[Autom. eng. transl.] Anti-HPV vaccination in Italy and Europe: state of the art and critical issues'. Together they form a unique fingerprint.

Cite this